Rheumatology - the Favored Few
A routine visit, followed by a few post-visit comments from the familly, is all it takes to remind me how great it is to be a rheumatologist.
A routine visit, followed by a few post-visit comments from the familly, is all it takes to remind me how great it is to be a rheumatologist.
Travel can be challenging for arthritis patients. Here are some useful tips to travel smoothly and pain free.
The prevention of Herpes zoster infections can be challenging in patients receiving immunosuppressives or biologic therapies. Dr. Artie Kavanugh reviews a new, potential advance in vaccination for shingles.
I had just finished going over the prognosis and treatment plan with my newly diagnosed rheumatoid arthritis patient. I asked if she had any questions for me. She did.
Comorbidities often influence the choice of therapies in RA. This elderly man with hepatitis and TB needs aggressive treatment, but what drugs can reasonably be considered?
Inefficient peer-to-peer physician communication has eroded integrated care and compromised patient outcomes and safety. Picking up the smart phone and use of technology may help to close these gaps.
Many rheumatologists need to go through the recertification process. The ABIM handling of this "requirement" has generated heated discussions over what appears to be an expensive, onerous, and irrelevant effort.
In this edition of “Across the Table”, Drs. Cush and Schwartman discuss uveitis. Our expert, Dr. Sergio Schwartzman offers up his approach to diagnosis and management.
What is going on in the wide and wacky world of pain and fatigue? What use to be called fibromyalgia is being reclassified as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. Although fibromyalgia has many faces, it does not deserve many names.
Fatigue is not far behind pain as the complaint that affects the quality of life in numerous rheumatic and autoimmune disorders. But do we need to focus on fatigue in our disease management?
There are no detailed recommendations agreed upon by SLE experts on what treatment to use after first and second (and often third) line treatment has failed.
If you’re going to spend 10-20% of your clinic hours examining and caring for 28 or 68 or 360 joints – it may be instructive to own up to those joints we excel at and take note of the ones we avoid, despise or struggle with.